Overview

Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17

Status:
Completed
Trial end date:
2011-03-16
Target enrollment:
Participant gender:
Summary
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Lisdexamfetamine Dimesylate
Methylphenidate